Document Detail


Use of echocardiography to evaluate the cardiac effects of therapies used in cancer treatment: what do we know?
MedLine Citation:
PMID:  23000452     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Cardiologists and oncologists today face the daunting challenge of identifying patients at risk for late-onset left ventricular (LV) systolic dysfunction from the use of various chemotherapeutic agents. Currently, the most widely used method in clinical practice for monitoring the potential of chemotherapy-induced cardiotoxicity is calculation of LV ejection fraction. The use of LV ejection fraction to determine whether to continue or discontinue the use of chemotherapeutic agents is limited, because decreases in LV ejection fraction frequently occur late and can be irreversible. These limitations have led to the exploration of diastolic function and newer modalities that assess myocardial mechanics to identify sensitive and specific variables that can predict the occurrence of late systolic function. The cancer therapies associated with cardiotoxicity are reviewed in this report. Additionally, the authors evaluate the role of present-day echocardiographic parameters, complementary noninvasive imaging modalities, and biomarkers in the prediction of cardiotoxicity. The authors address the evolving role of cardioprotective agents and potential therapies to prevent or reverse the progression of LV systolic dysfunction. Finally, they provide some ideas regarding future directions to enhance the knowledge of predicting late-onset LV systolic dysfunction secondary to cancer therapy.
Authors:
Lilia Oreto; Maria Chiara Todaro; Matt M Umland; Christopher Kramer; Rubina Qamar; Scipione Carerj; Bijoy K Khandheria; Timothy E Paterick
Publication Detail:
Type:  Journal Article; Review     Date:  2012-09-20
Journal Detail:
Title:  Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography     Volume:  25     ISSN:  1097-6795     ISO Abbreviation:  J Am Soc Echocardiogr     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-10-23     Completed Date:  2013-04-15     Revised Date:  2013-09-18    
Medline Journal Info:
Nlm Unique ID:  8801388     Medline TA:  J Am Soc Echocardiogr     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1141-52     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 American Society of Echocardiography. Published by Mosby, Inc. All rights reserved.
Affiliation:
Clinical and Experimental Department of Medicine and Pharmacology, University of Messina, Messina, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / adverse effects*,  therapeutic use*
Echocardiography / methods*
Humans
Neoplasms / complications,  drug therapy*
Outcome Assessment (Health Care) / methods*
Treatment Outcome
Ventricular Dysfunction, Left / chemically induced*,  prevention & control,  ultrasonography*
Chemical
Reg. No./Substance:
0/Antineoplastic Agents
Comments/Corrections
Erratum In:
J Am Soc Echocardiogr. 2013 Aug;26(8):845

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Plants as a source of butyrylcholinesterase variants designed for enhanced cocaine hydrolase activit...
Next Document:  Differential expression of miRNAs in rhabdomyosarcoma and malignant rhabdoid tumor.